Inogen (INGN) Stock Forecast, Price Target & Predictions
INGN Stock Forecast
Inogen stock forecast is as follows: an average price target of $26.00 (represents a 187.93% upside from INGN’s last price of $9.03) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
INGN Price Target
The average price target for Inogen (INGN) is $26.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $26.00 to $26.00. This represents a potential 187.93% upside from INGN's last price of $9.03.
INGN Analyst Ratings
According to 2 Wall Street analysts, Inogen's rating consensus is 'Buy'. The analyst rating breakdown for INGN stock is 0 'Strong Buy' (0.00%), 1 'Buy' (50.00%), 1 'Hold' (50.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Inogen Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 14, 2023 | Mike Matson | Needham | $26.00 | $8.82 | 194.78% | 187.93% |
The latest Inogen stock forecast, released on Jul 14, 2023 by Mike Matson from Needham, set a price target of $26.00, which represents a 194.78% increase from the stock price at the time of the forecast ($8.82), and a 187.93% increase from INGN last price ($9.03).
Inogen Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $9.03 | $9.03 | $9.03 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Inogen stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inogen's last price of $9.03. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Feb 15, 2024 | William Blair | - | Outperform | Upgrade |
| Jul 14, 2023 | Needham | - | Hold | Downgrade |
Inogen's last stock rating was published by William Blair on Feb 15, 2024. The company Upgrade its INGN rating from "null" to "Outperform".
Inogen Financial Forecast
Inogen Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $75.90M | $83.97M | $83.64M | $72.16M | $88.09M | $105.39M | $103.38M | $80.39M | $76.40M | $93.11M | $101.56M | $86.93M | $73.98M | $74.33M | $71.69M | $88.49M | $78.92M | $91.76M |
| Avg Forecast | $83.93M | $93.34M | $97.38M | $85.63M | $82.15M | $89.58M | $91.37M | $80.42M | $76.57M | $84.14M | $82.50M | $73.66M | $76.96M | $82.58M | $92.16M | $74.62M | $89.49M | $97.72M | $100.64M | $76.56M | $75.98M | $86.69M | $88.75M | $79.39M | $69.64M | $76.06M | $79.96M | $82.00M | $86.41M | $91.65M |
| High Forecast | $83.93M | $93.34M | $97.38M | $85.63M | $82.15M | $89.58M | $91.37M | $80.42M | $76.57M | $87.48M | $82.50M | $73.67M | $77.95M | $82.83M | $92.16M | $74.62M | $89.49M | $97.72M | $100.64M | $76.56M | $75.98M | $86.69M | $88.75M | $79.39M | $69.64M | $76.06M | $79.96M | $82.00M | $86.41M | $91.65M |
| Low Forecast | $83.93M | $93.34M | $97.38M | $85.63M | $82.15M | $89.58M | $91.37M | $80.42M | $76.57M | $81.99M | $82.50M | $73.66M | $75.97M | $82.34M | $92.16M | $74.62M | $89.49M | $97.72M | $100.64M | $76.56M | $75.98M | $86.69M | $88.75M | $79.39M | $69.64M | $76.06M | $79.96M | $82.00M | $86.41M | $91.65M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.99% | 1.02% | 0.91% | 0.97% | 0.98% | 1.08% | 1.03% | 1.05% | 1.01% | 1.07% | 1.14% | 1.10% | 1.06% | 0.98% | 0.90% | 1.08% | 0.91% | 1.00% |
Inogen's average Quarter revenue forecast for Mar 24 based on 2 analysts is $73.66M, with a low forecast of $73.66M, and a high forecast of $73.67M. INGN's average Quarter revenue forecast represents a -2.94% decrease compared to the company's last Quarter revenue of $75.90M (Dec 23).
Inogen EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-28.98M | $-46.72M | $-7.46M | $-17.83M | $51.81M | $-10.29M | $2.97M | $-7.83M | $-906.00K | $11.90M | $16.91M | $2.97M | $-595.00K | $2.74M | $2.13M | $2.28M | $-703.00K | $11.77M |
| Avg Forecast | $133.43K | $148.39K | $154.80K | $136.14K | $130.60K | $142.41K | $145.25K | $127.84K | $121.72K | $133.76K | $131.16K | $-10.29M | $122.34K | $131.29K | $146.51K | $-8.14M | $-874.93K | $155.35K | $159.99K | $-6.43M | $120.79K | $137.82K | $141.09K | $4.61M | $110.70K | $120.92K | $127.11K | $3.78M | $137.37K | $145.71K |
| High Forecast | $133.43K | $148.39K | $154.80K | $136.14K | $130.60K | $142.41K | $145.25K | $127.84K | $121.72K | $139.07K | $131.16K | $-8.23M | $123.93K | $131.68K | $146.51K | $-6.51M | $-699.94K | $155.35K | $159.99K | $-5.15M | $120.79K | $137.82K | $141.09K | $5.53M | $110.70K | $120.92K | $127.11K | $4.54M | $137.37K | $145.71K |
| Low Forecast | $133.43K | $148.39K | $154.80K | $136.14K | $130.60K | $142.41K | $145.25K | $127.84K | $121.72K | $130.34K | $131.16K | $-12.35M | $120.78K | $130.90K | $146.51K | $-9.76M | $-1.05M | $155.35K | $159.99K | $-7.72M | $120.79K | $137.82K | $141.09K | $3.69M | $110.70K | $120.92K | $127.11K | $3.03M | $137.37K | $145.71K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -236.89% | -355.87% | -50.92% | 2.19% | -59.22% | -66.25% | 18.58% | 1.22% | -7.50% | 86.32% | 119.87% | 0.64% | -5.37% | 22.65% | 16.75% | 0.60% | -5.12% | 80.77% |
2 analysts predict INGN's average Quarter EBITDA for Mar 23 to be $-8.14M, with a high of $-6.51M and a low of $-9.76M. This is -115.70% lower than Inogen's previous annual EBITDA (Dec 22) of $51.81M.
Inogen Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-26.55M | $-45.72M | $-9.83M | $-20.35M | $-56.61M | $-9.51M | $-3.44M | $-14.21M | $-22.88M | $12.17M | $5.10M | $-732.00K | $-5.12M | $-1.70M | $2.58M | $-1.59M | $-1.38M | $6.86M |
| Avg Forecast | $-9.82M | $-8.65M | $-9.09M | $-10.26M | $-9.75M | $-8.61M | $-9.27M | $-10.49M | $-13.43M | $-11.71M | $-10.96M | $-17.84M | $-14.78M | $-28.66M | $-14.03M | $-14.10M | $-17.84M | $-9.92M | $-8.74M | $-11.15M | $-17.19M | $-5.90M | $-2.60M | $-1.24M | $-6.30M | $425.07K | $-1.81M | $-2.17M | $2.44M | $5.47M |
| High Forecast | $-9.82M | $-8.65M | $-9.09M | $-10.26M | $-9.75M | $-8.61M | $-9.27M | $-10.49M | $-13.43M | $-9.64M | $-10.96M | $-14.27M | $-12.96M | $-28.66M | $-14.03M | $-11.28M | $-14.27M | $-9.92M | $-8.74M | $-8.92M | $-17.19M | $-5.90M | $-2.60M | $-995.52K | $-6.30M | $425.07K | $-1.81M | $-1.73M | $2.44M | $5.47M |
| Low Forecast | $-9.82M | $-8.65M | $-9.09M | $-10.26M | $-9.75M | $-8.61M | $-9.27M | $-10.49M | $-13.43M | $-14.23M | $-10.96M | $-21.41M | $-16.14M | $-28.66M | $-14.03M | $-16.92M | $-21.41M | $-9.92M | $-8.74M | $-13.38M | $-17.19M | $-5.90M | $-2.60M | $-1.49M | $-6.30M | $425.07K | $-1.81M | $-2.60M | $2.44M | $5.47M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.80% | 1.60% | 0.70% | 1.44% | 3.17% | 0.96% | 0.39% | 1.28% | 1.33% | -2.06% | -1.96% | 0.59% | 0.81% | -4.00% | -1.43% | 0.73% | -0.56% | 1.25% |
Inogen's average Quarter net income forecast for Dec 21 is $-17.19M, with a range of $-17.19M to $-17.19M. INGN's average Quarter net income forecast represents a -241.22% decrease compared to the company's last Quarter net income of $12.17M (Sep 21).
Inogen SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $50.43M | $43.10M | $41.52M | $47.30M | $29.86M | $48.51M | $43.07M | $43.23M | $40.58M | $37.56M | $34.54M | $37.99M | $35.91M | $31.47M | $31.81M | $36.94M | $35.62M | $32.57M |
| Avg Forecast | $37.47M | $41.67M | $43.47M | $38.23M | $36.67M | $39.99M | $40.79M | $35.90M | $34.18M | $37.56M | $36.83M | $54.25M | $34.36M | $36.87M | $41.14M | $42.89M | $31.64M | $43.62M | $44.93M | $33.90M | $33.92M | $38.70M | $39.62M | $64.58M | $31.09M | $33.96M | $35.70M | $50.37M | $38.58M | $40.92M |
| High Forecast | $37.47M | $41.67M | $43.47M | $38.23M | $36.67M | $39.99M | $40.79M | $35.90M | $34.18M | $39.05M | $36.83M | $65.11M | $34.80M | $36.98M | $41.14M | $51.47M | $37.97M | $43.62M | $44.93M | $40.69M | $33.92M | $38.70M | $39.62M | $77.50M | $31.09M | $33.96M | $35.70M | $60.45M | $38.58M | $40.92M |
| Low Forecast | $37.47M | $41.67M | $43.47M | $38.23M | $36.67M | $39.99M | $40.79M | $35.90M | $34.18M | $36.60M | $36.83M | $43.40M | $33.92M | $36.76M | $41.14M | $34.31M | $25.31M | $43.62M | $44.93M | $27.12M | $33.92M | $38.70M | $39.62M | $51.67M | $31.09M | $33.96M | $35.70M | $40.30M | $38.58M | $40.92M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.47% | 1.17% | 1.01% | 1.10% | 0.94% | 1.11% | 0.96% | 1.28% | 1.20% | 0.97% | 0.87% | 0.59% | 1.16% | 0.93% | 0.89% | 0.73% | 0.92% | 0.80% |
Inogen's average Quarter SG&A projection for Mar 24 is $54.25M, based on 2 Wall Street analysts, with a range of $43.40M to $65.11M. The forecast indicates a 7.59% rise compared to INGN last annual SG&A of $50.43M (Dec 23).
Inogen EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 13 | 8 | 8 | 9 | 12 | 7 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.00 | $-1.97 | $-0.42 | $-0.88 | $-2.47 | $-0.42 | $-0.15 | $-0.62 | $-1.01 | $0.54 | $0.23 | $-0.03 | $-0.23 | $-0.08 | $0.12 | $-0.07 | $-0.06 | $0.31 |
| Avg Forecast | $-0.42 | $-0.37 | $-0.38 | $-0.43 | $-0.41 | $-0.36 | $-0.39 | $-0.44 | $-0.57 | $-0.50 | $-0.46 | $-0.76 | $-0.63 | $-1.21 | $-0.59 | $-0.78 | $-0.57 | $-0.42 | $-0.37 | $-0.47 | $-0.73 | $-0.25 | $-0.11 | $-0.27 | $-0.27 | $0.02 | $-0.08 | $-0.11 | $0.10 | $0.23 |
| High Forecast | $-0.42 | $-0.37 | $-0.38 | $-0.43 | $-0.41 | $-0.36 | $-0.39 | $-0.44 | $-0.57 | $-0.41 | $-0.46 | $-0.76 | $-0.55 | $-1.21 | $-0.59 | $-0.78 | $-0.57 | $-0.42 | $-0.37 | $-0.47 | $-0.73 | $-0.25 | $-0.11 | $-0.27 | $-0.27 | $0.02 | $-0.08 | $-0.11 | $0.10 | $0.23 |
| Low Forecast | $-0.42 | $-0.37 | $-0.38 | $-0.43 | $-0.41 | $-0.36 | $-0.39 | $-0.44 | $-0.57 | $-0.60 | $-0.46 | $-0.76 | $-0.68 | $-1.21 | $-0.59 | $-0.78 | $-0.57 | $-0.42 | $-0.37 | $-0.47 | $-0.73 | $-0.25 | $-0.11 | $-0.27 | $-0.27 | $0.02 | $-0.08 | $-0.11 | $0.10 | $0.23 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 1.62% | 0.71% | 1.13% | 4.30% | 1.00% | 0.41% | 1.31% | 1.39% | -2.16% | -2.09% | 0.12% | 0.86% | -4.29% | -1.57% | 0.65% | -0.61% | 1.34% |
According to 2 Wall Street analysts, Inogen's projected average Quarter EPS for Dec 21 is $-0.73, with a low estimate of $-0.73 and a high estimate of $-0.73. This represents a -234.81% decrease compared to INGN previous annual EPS of $0.54 (Sep 21).
Inogen Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| APYX | Apyx Medical | $1.16 | $8.50 | 632.76% | Buy |
| INGN | Inogen | $9.03 | $26.00 | 187.93% | Buy |
| SGHT | Sight Sciences | $4.66 | $10.25 | 119.96% | Hold |
| NPCE | NeuroPace | $6.37 | $12.88 | 102.20% | Buy |
| OFIX | Orthofix Medical | $17.33 | $31.00 | 78.88% | - |
| LUNG | Pulmonx | $7.12 | $11.93 | 67.56% | Buy |
| SIBN | SI-BONE | $13.63 | $20.00 | 46.74% | Buy |
| KIDS | OrthoPediatrics | $28.74 | $39.60 | 37.79% | Buy |
| CNMD | CONMED | $70.47 | $96.00 | 36.23% | Buy |
| AORT | Artivion | $27.46 | $30.60 | 11.43% | Buy |
| ITGR | Integer | $126.53 | $138.00 | 9.07% | Buy |
| CVRX | CVRx | $15.05 | $16.33 | 8.50% | Buy |
| SRDX | Surmodics | $37.57 | $39.50 | 5.14% | Buy |
INGN Forecast FAQ
Is Inogen a good buy?
Yes, according to 2 Wall Street analysts, Inogen (INGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 1 'Buy' recommendations, accounting for 50.00% of INGN's total ratings.
What is INGN's price target?
Inogen (INGN) average price target is $26 with a range of $26 to $26, implying a 187.93% from its last price of $9.03. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Inogen stock go up soon?
According to Wall Street analysts' prediction for INGN stock, the company can go up by 187.93% (from the last price of $9.03 to the average price target of $26), up by 187.93% based on the highest stock price target, and up by 187.93% based on the lowest stock price target.
Can Inogen stock reach $14?
INGN's average twelve months analyst stock price target of $26 supports the claim that Inogen can reach $14 in the near future.
What are Inogen's analysts' financial forecasts?
Inogen's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $343.51M (high $343.51M, low $343.51M), average EBITDA is $546.1K (high $546.1K, low $546.1K), average net income is $-38.13M (high $-38.13M, low $-38.13M), average SG&A $153.35M (high $153.35M, low $153.35M), and average EPS is $-1.615 (high $-1.615, low $-1.615). INGN's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $360.28M (high $360.28M, low $360.28M), average EBITDA is $572.76K (high $572.76K, low $572.76K), average net income is $-37.815M (high $-37.815M, low $-37.815M), average SG&A $160.84M (high $160.84M, low $160.84M), and average EPS is $-1.601 (high $-1.601, low $-1.601).
Did the INGN's actual financial results beat the analysts' financial forecasts?
Based on Inogen's last annual report (Dec 2023), the company's revenue was $315.66M, which missed the average analysts forecast of $326.32M by -3.27%. Apple's EBITDA was $-109M, beating the average prediction of $-7.737M by 1313.89%. The company's net income was $-102M, beating the average estimation of $-71.563M by 43.16%. Apple's SG&A was $182.35M, beating the average forecast of $155.26M by 17.45%. Lastly, the company's EPS was $-0.0044, missing the average prediction of $-3.213 by -99.86%. In terms of the last quarterly report (Dec 2023), Inogen's revenue was $75.9M, missing the average analysts' forecast of $76.96M by -1.38%. The company's EBITDA was $-28.982M, missing the average prediction of $122.34K by -23788.75%. Inogen's net income was $-26.555M, beating the average estimation of $-14.776M by 79.72%. The company's SG&A was $50.43M, beating the average forecast of $34.36M by 46.77%. Lastly, the company's EPS was $-0.0011, missing the average prediction of $-0.626 by -99.82%